Max Morgan

Max Morgan

Auto-generated profile, based on publicly available information

Max Morgan

Structural Genomics Consortium, University of Toronto, Toronto, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
SASuzanne Ackloo
Suzanne Ackloo
RARima Al-Awar
Rima Al-Awar
RARommie Amaro
Rommie Amaro
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
HAHatylas Azevedo
Hatylas Azevedo
TWTimothy M. Willson
Timothy M. Willson

3 December 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
SMSusanne Müller
Susanne Müller
SASuzanne Ackloo
Suzanne Ackloo
ACArij Al Chawaf
Arij Al Chawaf
BABissan Al-Lazikani
Bissan Al-Lazikani
AAAlbert Antolin
Albert Antolin
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. Target 2035 aims to develop a pharmacological modulator for every protein in the human proteome to fill this gap.

15 April 2002 in Journal of Virology
Verified
Journal Article
Open access
PDF file
MKMasanori Kameoka
Masanori Kameoka
MMMax Morgan
Max Morgan
MBMarc Binette
Marc Binette
RRRodney S. Russell
Rodney S. Russell
LRLiwei Rong
Liwei Rong
MWMark Wainberg
Mark Wainberg
Human immunodeficiency virus type-1 Tat has been proposed to play a role in the regulation of reverse transcription. We previously demonstrated that wild-type Tat can augment viral infectivity by suppressing the reverse transcriptase (RT) reaction at late stages of the viral life cycle in order to prevent the premature synthesis of potentially deleterious viral DNA products. Here we have performed a detailed analysis of the cell-free reverse transcription reaction to elucidate the mechanism(s) whereby Tat can affect this process. Our results show that Tat can suppress nonspecific DNA elongation while moderately affecting the specific initiation stage of reverse transcription. In addition, Tat has an RNA-annealing activity and can promote the placement of tRNA onto viral RNA. This points to a functional homology between Tat and the viral nucleocapsid (NC) protein that is known to be directly involved in this process. Experiments using a series of mutant Tat proteins revealed that the cysteine-rich and core domains of Tat are responsible for suppression of DNA elongation, while each of the cysteine-rich, core, and basic domains, as well as a glutamine-rich region in the C-terminal domain, are important for the placement of tRNA onto the viral RNA genome. These results suggest that Tat can play at least two different roles in the RT reaction, i.e., suppression of DNA polymerization and placement of tRNA onto viral RNA. We believe that the first of these activities of Tat may contribute to the overall efficiency of reverse transcription of the viral genome during a new round of infection as well as to enhanced production of infectious viral particles. We hypothesize that the second activity, illustrating functional homology between Tat and NC, suggests a potential role for NC in the displacement of Tat during viral maturation.

6 December 2018 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
MMMaxwell Robert Morgan
Maxwell Robert Morgan
OROwen Gwilym Roberts
Owen Gwilym Roberts
AEAled Morgan Edwards
Aled Morgan Edwards
M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science. The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.

31 May 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
AEAled Edwards
Aled Edwards
MMMax Morgan
Max Morgan
ACArij Al Chawaf
Arij Al Chawaf
KAKerry Andrusiak
Kerry Andrusiak
RCRachel Charney
Rachel Charney
WZWilliam J. Zuercher
William J. Zuercher
The core feature of trusts—holding property for the benefit of others—is well suited to constructing a research community that treats reagents as public goods.

23 June 2016 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
DRDamian Rolfe
Damian Rolfe
JPJayson Parker
Jayson Parker
MMMax Morgan
Max Morgan
Introduction: This paper explores whether, and under what circumstances, a biosimilar approved in the United States under the Biologics Price Competition and Innovation Act (hereafter ‘BPCIA’) can be patented. The possibility that a biosimilar product could have meaningful patent protection arises from specific requirements for biosimilarity under the BPCIA, which account for the fact that manufacturing processes of biologics are inherently imprecise. The requirements for biosimilar approval may provide sufficient leeway to a biosimilar applicant to patent structural or formulation differences that provide non-clinical but business-relevant advantages over the reference molecule, such as improved shelf-life or ease of manufacture, without compromising clinical biosimilarity. Areas covered: Examination of the BPCIA and related Acts, Food and Drug Administration (FDA) guidance papers, case law, patent database searching, and relevant scholarly articles. Expert opinion: Legislative and regulatory requirements for the approval of a biosimilar under the BPCIA are focused on clinical results and allow a degree of leeway for differences to exist between a biosimilar’s structure and non-clinical components and those of the biosimilar’s reference molecule. This leeway can be exploited to provide the biosimilar with potentially patentable business-relevant advantages over its reference product while maintaining clinical biosimilarity to the reference product.